ERBB2 and neoplasm: Clinical decision making for invasive breast cancer is being increasingly informed by molecular properties of the tumor, including hormone receptor or HER2 overexpression), and Oncotype DX has made analysis of gene expression for both prognosis and predicting response to therapy clinically relevant [4, 5].